...
首页> 外文期刊>Scandinavian journal of clinical and laboratory investigation. >Prognostic utility of combination of NT-proBNP with high sensitive cTn I in patients with heart failure: Results from retrospective study in an emergency department
【24h】

Prognostic utility of combination of NT-proBNP with high sensitive cTn I in patients with heart failure: Results from retrospective study in an emergency department

机译:NT-proBNP与高敏感性cTn I联合在心力衰竭患者中的​​预后作用:急诊科的回顾性研究结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: N-terminal proBNP (NT-proBNP) and cardiac troponin I (cTn I) are widely used for the diagnosis of myocardial injury, but have not been used for routine evaluation in heart failure (HF) population.Aims: To evaluate the prognostic utility of combination of NT-proBNP and cTn I in patients with HF, including serial NT-proBNP/cTn I measurements and discharge NT-proBNP/cTn I levels.Patients and methods: A total of 610 patients presenting in our emergency department for acute HF were studied. The mortality and HF-related readmission were endpoints in the study. NT-proBNP and cTn I were tested on admission including first 5 consecutive days, and on discharge.Results: A discharge cTn I cut-off value at 24ng/L and discharge NT-proBNP cut-off value at 350ng/L were determined. The cTn I level more than 24ng/L and NT-proBNP level more than 350ng/L are associated with increased risk for mortality and readmission (p<0.01). The mortality and HF-related readmission was significantly increased in patients with high cTn I+high NT-proBNP (p<0.05), high cTn I+low NT-proBNP (p<0.05), and low cTn I+high NT-proBNP (p<0.0%). The increased cTn I or increased NT-proBNP measured in the first 5 consecutive days were significantly associated with 60-day HF-related events (p<0.05), but the serial measurements did not have a predictive value of 1-year HF outcome.Conclusion: This study demonstrates that elevations of discharge cTn I and NT-proBNP are associated with increased 1-year mortality and HF-related readmission. Patients with increasing serial cTnI and NT-proBNP had increased risk for 60-day HF-related events. The two markers can act as independent predicators, and complete each other in prognostic utility of HF patients.
机译:背景:N末端proBNP(NT-proBNP)和心肌肌钙蛋白I(cTn I)被广泛用于诊断心肌损伤,但尚未用于心力衰竭(HF)人群的常规评估。 NT-proBNP和cTn I联合在HF患者中的预后效用,包括连续的NT-proBNP / cTn I测量和出院NT-proBNP / cTn I水平。患者和方法:共有610名患者在我们的急诊科就诊。研究了急性HF。死亡率和HF相关的再入院是研究的终点。入院前连续5天对NT-proBNP和cTn I进行检测,并进行放电。结果:确定了24ng / L处的cTn I排出临界值和350ng / L处的NT-proBNP排出临界值。高于24ng / L的cTn I水平和高于350ng / L的NT-proBNP水平与死亡率和再入院风险增加相关(p <0.01)。高cTn I +高NT-proBNP(p <0.05),高cTn I +低NT-proBNP(p <0.05)和低cTn I +高NT-proBNP的患者的死亡率和HF相关的再入院显着增加(p <0.0%)。在连续5天中测得的cTn I升高或NT-proBNP升高与60天的HF相关事件显着相关(p <0.05),但连续测量没有1年HF结果的预测值。结论:这项研究表明,排出cTn I和NT-proBNP的升高与1年死亡率的增加和HF相关的再入院有关。连续性cTnI和NT-proBNP升高的患者发生60天HF相关事件的风险增加。这两种标记物可以充当独立的谓词,并且在HF患者的预后效用中彼此互补。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号